1.687
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference - The Manila Times
Gain Therapeutics to Present at BTIG's Annual Biotechnology Conference. - AInvest
Gain Therapeutics Leadership Team Set for Exclusive Fireside Chat at BTIG Annual Biotech Conference - Stock Titan
Gain Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital gains - Autocar Professional
Is Indaptus Therapeutics Inc. a good long term investmentRapid market gains - jammulinksnews.com
What analysts say about Gain Therapeutics Inc. stockMarket-leading growth rates - printweek.in
What drives Gain Therapeutics Inc. stock priceRemarkably fast returns - jammulinksnews.com
What drives Monte Rosa Therapeutics Inc. stock priceExplosive portfolio gains - Autocar Professional
Aardvark Therapeutics Inc. Stock Analysis and ForecastHigh-octane gains - jammulinksnews.com
What drives Allogene Therapeutics Inc. stock priceTremendous gains - jammulinksnews.com
Is Nurix Therapeutics Inc. a good long term investmentSkyrocketing investment returns - Jammu Links News
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX), Abbott Laboratories (ABT) and ANI Pharmaceuticals (ANIP) - The Globe and Mail
Is Grace Therapeutics Inc. a good long term investmentTremendous gains - jammulinksnews.com
Healthcare Stocks to Watch: Gain Therapeutics, Abbott Laboratories, and ANI Pharmaceuticals - AInvest
Is vTv Therapeutics Inc. a good long term investmentTremendous gains - Jammu Links News
Bicara Therapeutics Inc. Stock Analysis and ForecastHigh-velocity gains - jammulinksnews.com
What drives Mineralys Therapeutics Inc. stock priceHigh-octane gains - Jammu Links News
Is Soleno Therapeutics Inc. a good long term investmentSuperior trading gains - Jammu Links News
What drives Avalo Therapeutics Inc. stock priceExceptional risk-adjusted gains - Jammu Links News
What analysts say about Gain Therapeutics Inc. stock outlookLow Risk High Reward Picks - Newser
Does Avalo Therapeutics Inc. stock pay reliable dividendsReal Time Alert Service - Newser
Is Heron Therapeutics Inc. stock a good hedge against inflationDaily Gain Forecast - Newser
What risks could impact LOGC stock performanceFree Expert-Led Investment Training - Newser
Gain Therapeutics Announces $7 Million Public Offering - TipRanks
Form 424B5 Gain Therapeutics, Inc. - StreetInsider
How Nurix Therapeutics Inc. stock performs during market volatility200 Percent Gain Alert - Newser
Why Gain Therapeutics Inc. stock attracts strong analyst attentionDaily Stock Radar - beatles.ru
Neurodegenerative Biotech's Capital Crunch: The Dilution Dilemma in $7M Offerings - AInvest
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering - The Manila Times
Gain Therapeutics on pricing stock-and-warrants offering - TradingView
Gain Therapeutics Secures $7M Funding to Advance Novel Parkinson's Treatment Pipeline - Stock Titan
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus - Benzinga
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Gain Therapeutics' High-Stakes Gamble: Can GT-02287 Rewrite the Neurodegenerative Treatment Playbook? - AInvest
Gain Therapeutics Plans Public Offering of Common Shares, Warrants - MarketScreener
Gain Therapeutics falls on equity offering plans - TradingView
Gain Therapeutics Announces Proposed Public Offering - The Manila Times
Gain Therapeutics stock falls after announcing public offering By Investing.com - Investing.com Canada
Gain Therapeutics stock falls after announcing public offering - Investing.com
Gain Therapeutics, Inc. Proposes Underwritten Public Offering of Common Stock and Warrants - Nasdaq
Gain Therapeutics Unveils Strategic Public Offering: Funding Next-Gen Parkinson's Treatment Development - Stock Titan
Why Alaunos Therapeutics Inc. stock attracts strong analyst attentionRapid Gain Targets - Newser
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):